000			02319nam a2200457 i 4500
999			_c278145 _d278145
001			on1078951640
003			OCoLC
005			20190121092913.0
006			m o d f
007			cr bn||||a||||
008			181214s2018 dcua ob f000 0 eng c
040			_aPUCPR _beng _erda _epn _cGPO _dMvI
042			_apcc
043			_an-us---
074			_a1043-C (online)
086	0		_aY 4.L 11/4:S.HRG.114-805
099			_aY 4.L 11/4:S.HRG.114-805
110	1		_aUnited States. _bCongress. _bSenate. _bCommittee on Health, Education, Labor, and Pensions. _bSubcommittee on Children and Families,
245	1	0	_aEpiPen price increases : _bhow regulatory barriers inhibit pharmaceutical competition : field hearing of the Subcommittee on Children and Families of the Committee on Health, Education, Labor, and Pensions, United States Senate, One Hundred Fourteenth Congress, second session on examining EpiPen price increases, focusing on how regulatory barriers inhibit pharmaceutical competition, October 7, 2016 (Lexington, KY).
246	3	0	_aHow regulatory barriers inhibit pharmaceutical competition
264		1	_aWashington : _bU.S. Government Publishing Office, _c2018.
300			_a1 online resource (iii, 43 pages) : _billustrations.
336			_btxt
337			_bc _2rdamedia
338			_bcr _2rdacarrier
490	1		_aS. hrg. ; _v114-805
500			_aCRDP Program record.
504			_aIncludes bibliographical references.
588			_aDescription based on online resource; title from PDF title page (govinfo web site, viewed on December 14, 2018).
776	0	8	_iPrint version: _aUnited States. Congress. Senate. Committee on Health, Education, Labor, and Pensions. Subcommittee on Children and Families. _tEpiPen price increases _w(OCoLC)1078409593
810	1		_aUnited States. _bCongress. _bSenate. _tS. hrg. ; _v114-805.
856	4	0	_uhttps://purl.fdlp.gov/GPO/gpo113215
050		4	_aKF26 _b.L2733 2016
650		0	_aPrescription pricing _zUnited States.
650		0	_aDrugs _xLaw and legislation _zUnited States.
650		0	_aPharmaceutical industry _zUnited States.
650		0	_aCompetition _zUnited States.
650		0	_aDrug delivery devices _xPrices _zUnited States.
655		7	_aLegislative hearings. _2lcgft
942			_2sudocs _c8